A Phase 1/2 interventional study of NGM282 and Placebo in Functional Constipation, sponsored by NGM Biopharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-30.
Sponsored by NGM Biopharmaceuticals, Inc · Phase 1/2, Interventional, and Treatment
The purpose of this study is to determine the effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and healthy individuals.
1,018 studies on the registry are indexed under Constipation; 139 are open to participants now.
This study's enrollment of 31 is below the median of 80 across 850 interventional studies indexed under Constipation.
Browse Constipation studies →NGM Biopharmaceuticals, Inc is the lead sponsor of 26 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
NGM282
Biological: NGM282
NGM282
Biological: NGM282
Placebo
Other: Placebo
Effect on Colon Transit, as measured by the movement of food through the colon
Time frame: 9 days
Clinical Laboratory Assessments
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NGM Biopharmaceuticals, Inc